ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GLSI
BCYC (20) LRMR (34) AMRN (32) ABEO (23) ⌘ Pro Terminal →

Greenwich LifeSciences Inc. (GLSI) — RQD Stock Rating Cockpit

$16.46 -5.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $16.27

Greenwich LifeSciences Inc. (GLSI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $255.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GLSI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GLSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Greenwich LifeSciences Inc. (NASDAQ: GLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $16.46 (-5.46% 1D, market cap $255.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GLSI ranks #759 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GLSI compare to BCYC and LRMR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GLSI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCYC (Bicycle Therapeutics plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $256.5M) and LRMR (Larimar Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $256.6M). Among the 5-stock peer group, GLSI leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GLSI?
▼

Per GLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799788), Greenwich LifeSciences Inc. generated $54.5M in revenue (+10.3% YoY), -$19.4M in net income, and -$9.9M in free cash flow against $6.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $16.27 (-1.17%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (6)Whales (7)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
$36 Bull$14 Base$11 Bear
📬 FREE GLSI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GLSI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY GLSI SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
23
Grade E$15.50+4.8% Next Q
Q2 (-2Q)
26
Grade E$16.24+7.3% Next Q
Q3 (-1Q)
28
Grade E$17.42-5.5% Next Q
Current
31
Grade E$16.46-9.4% Hist 90D α
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GLSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GLSI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.80) and Max Pain ($17.28) forces dealer call-delta covering toward $35.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GLSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GLSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
51.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE33% OF RANGE
L: $8$16.46H: $34
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on GLSI

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 42.0% gross margin and -3.55% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (25)

10/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like GLSI
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GLSI)

  • ✓Walkthrough of GLSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GLSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.11%▼ DESCENDING CHANNEL
2026-11-03O $19.00H $19.00L $16.46C $16.46VOL 174.7K
RES: $19.31SUP: $13.97SMA50: $16.80SMA200: $21.46
$31.15$26.10$21.05$15.99$10.94RES $19.31SUP $13.97$16.462026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GLSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GLSI Butterfly Map → + Track GLSI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +10.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GLSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GLSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GLSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GLSI)

Health Care Rank #759 of 1015 ⚔️ BCYC vs GLSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GLSI vs. BCYC, LRMR, AMRN, ABEO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Greenwich LifeSciences Inc. (GLSI) ranks #759 by composite RQD confidence (31/100, grade E) and #537 by equity capitalization ($255.5M). Within this direct 5-issuer industry benchmark cohort, GLSI leads on earnings valuation at N/A trailing P/E, while AMRN leads on capital efficiency and profitability with -12.2% ROIC and 56.6% gross margin. LRMR currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with GLSI at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GLSI ACTIVE
Greenwich LifeSciences Inc.
E 31/100 — — -35.0% -5.46% $255.5M Benchmark Subject
BCYC
Bicycle Therapeutics plc
E 20/100 — — -35.0% -1.09% $256.5M /bcyc-vs-glsi →
LRMR
Larimar Therapeutics Inc.
E 34/100 — — -35.0% -4.05% $256.6M /lrmr-vs-glsi →
AMRN
Amarin Corporation plc
E 32/100 — 56.6% -12.2% +0.17% $249.9M /amrn-vs-glsi →
ABEO
Abeona Therapeutics Inc.
E 23/100 — 73.7% -35.0% -2.30% $248.8M /abeo-vs-glsi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001799788 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Greenwich LifeSciences Inc. (GLSI) reported GAAP revenue of $54.5M (+10.3% vs. FY2024 revenue of $49.4M , and +108.5% cumulative change since FY2023) , GAAP net income of -$19.4M, operating cash flow of -$9.9M, and free cash flow of -$9.9M (-36.4% YoY). On the balance sheet, GLSI closed FY2025 with $6.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $54.5M -$19.4M -$9.9M -$9.9M $6.2M —
FY2024 (FY) 2024-12-31 $49.4M -$17.4M -$7.3M -$7.3M $4.1M —
FY2023 (FY) 2023-12-31 $26.1M -$8.9M -$6.5M -$6.5M — —

3. GLSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GLSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Greenwich LifeSciences Inc. (NASDAQ: GLSI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $16.46 (-5.46% 1D, market cap $255.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GLSI ranks #759 in composite RQD confidence.

How does GLSI compare to BCYC and LRMR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GLSI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCYC (Bicycle Therapeutics plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $256.5M) and LRMR (Larimar Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $256.6M). Among the 5-stock peer group, GLSI leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GLSI?

Per GLSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799788), Greenwich LifeSciences Inc. generated $54.5M in revenue (+10.3% YoY), -$19.4M in net income, and -$9.9M in free cash flow against $6.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GLSI trading relative to its 50-day, 200-day, and 52-week technical levels?

GLSI last traded at $16.46 (-5.46% on volume of 118,612 shares), positioning the stock -2.02% below its 50-day simple moving average ($16.80) and -23.30% below its 200-day simple moving average ($21.46). Across its 52-week range of $7.78 to $34.10, GLSI sits at the 33.0% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($14.40 to $18.52).

Direct Sub-Reports: GLSI RQD Cockpit GLSI 12M Forecast GLSI Earnings & Move GLSI Dividends & DRIP GLSI Insiders & 13F GLSI Whale Options GLSI Profit Sankey GLSI News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

GLSI — Greenwich LifeSciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Greenwich LifeSciences Inc. (GLSI) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $16.46 (-5.46% 1D, market capitalization $255.5M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -3.55%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Greenwich LifeSciences Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. — regarding specific products, customers, or revenue model. The profile identifies a market capitalization of $0.3B. The company reports — revenue in each of the FY 2023, FY 2024, and FY 2025 periods, indicating no commercial revenue is recorded in the provided financials.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Greenwich LifeSciences Inc. (GLSI) reported $54.5M in annual revenue (up from $49.4M in FY2024, +10.3% YoY) and -$19.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($26.1M revenue, -$8.9M net income) through FY2025, GLSI scaled operating cash flow to -$9.9M and free cash flow to -$9.9M, backed by $6.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.55% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $7.78 – $34.10 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector correlation data is not provided beyond the Health Care sector classification and beta of 1.0.

  • Key Question #1: Can GLSI sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $54.5M and free cash flow of -$9.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is GLSI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GLSI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Greenwich LifeSciences Inc. (GLSI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GLSI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GLSI Bull vs. Bear Conversation Board — What's Your Call at $16.46?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GLSI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GLSI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $22.28 (+28.0%)
📌 Pinned Debate

Shares trade at $19 after a 52-week range of $7.78 to $34.1, showing the stock has already recovered substantially from its low.

Picked up a starter position in GLSI in my $100K Virtual Cash book at $17.41. Shares trade at $19 after a 52-week range of $7.78 to $34.1, showing the stock has already recovered substantially from its low.. Trading inside a $7.78–$34.10 52-week range with -3.55% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

CapAlloc_Nerd 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $13.41 (-23.0%)
Spot @ $17.41

Reported revenue is $0.0M in every period with FY 2025 operating income of -$19.4M and FCF of -$9.9M, against $6.2M of cash.

Reported revenue is $0.0M in every period with FY 2025 operating income of -$19.4M and FCF of -$9.9M, against $6.2M of cash.. Look at the math on GLSI: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $15.32 before getting long.

LIVE TAPE